<DOC>
	<DOC>NCT00726752</DOC>
	<brief_summary>This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses</brief_summary>
	<brief_title>A Study In Patients With Advanced Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients histologically or cytologically diagnosed with advanced solid tumors Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2 Patients with no uncontrolled hypertension Patients who have central lung lesions involving major blood vessels Patients who require anticoagulant therapy. Patients with active epilepsy seizure or symptoms, with brain metastases requiring treatment, with spinal cord compression and with carcinomatous meningitis.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>Axitinib</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase 1</keyword>
</DOC>